Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I–deficient and MHC I(+) tumors

Cyclic dinucleotides (CDN) and Toll-like receptor (TLR) ligands mobilize antitumor responses by natural killer (NK) cells and T cells, potentially serving as complementary therapies to immune checkpoint therapy. In the clinic thus far, however, CDN therapy targeting stimulator of interferon genes (S...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolf, Natalie K., Blaj, Cristina, Picton, Lora K., Snyder, Gail, Zhang, Li, Nicolai, Christopher J., Ndubaku, Chudi O., McWhirter, Sarah M., Garcia, K. Christopher, Raulet, David H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295797/
https://www.ncbi.nlm.nih.gov/pubmed/35588144
http://dx.doi.org/10.1073/pnas.2200568119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295797/
https://www.ncbi.nlm.nih.gov/pubmed/35588144
http://dx.doi.org/10.1073/pnas.2200568119

Ejemplares similares